Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study

References

• Elemento O, Reece R. The future of precision medicine: towards a more predictive personalized medicine. Emerg Top Life Sci. 2020;4(2):175–177. doi:10.1042/ETLS20190197
   PubMedGoogle Scholar
• Scott SA, Swen JJ. Pharmacogenomic determinants of interindividual drug response variability: from discovery to implementation. Genes. 2021;12(3):393. doi:10.3390/genes12030393
   PubMed Web of Science ®Google Scholar
• Peck RW. Precision medicine is not just genomics: the right dose for every patient. Annu Rev Pharmacol Toxicol. 2018;58(1):105–122. doi:10.1146/annurev-pharmtox-010617-052446
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence (NICE). Nice guideline. medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes; 2015. Available from: https://www.nice.org.uk/guidance/ng5. Accessed June 5, 2023.
   Google Scholar
• World Health Organization (WHO). Medication safety in polypharmacy; 2019. Available from: https://www.who.int/publications/i/item/WHO-UHC-SDS-2019.11. Accessed June 5, 2023.
   Google Scholar
• U.S. Food and Drug Administration (FDA). Working to reduce medication errors; 2019. Available from: https://www.fda.gov/drugs/information-consumers-and-patients-drugs/working-reduce-medication-errors. Accessed June 5, 2023.
   Google Scholar
• Meyer Zu Schwabedissen HE. The Role of Pharmacogenomics in Individualized Medicine. In: Fischer T, Langanke M, Marschall P, Michl S editors. Individualized Medicine: Ethical, Economical and Historical Perspectives. Advances in Predictive, Preventive and Personalised Medicine. Springer International Publishing; 2015:93–112. doi:10.1007/978-3-319-11719-5_7
   Google Scholar
• Jeiziner C, Suter K, Wernli U, et al. Pharmacogenetic information in Swiss drug labels – a systematic analysis. Pharmacogenomics J. 2020:1–12. doi:10.1038/s41397-020-00195-4
   Web of Science ®Google Scholar
• Research C for DE and Table of Pharmacogenomic Biomarkers in Drug Labeling. FDA. Available from: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling. Accessed June 5, 2023.
   Google Scholar
• van der Wouden CH, Paasman E, Teichert M, Crone MR, Guchelaar HJ, Swen JJ. Assessing the implementation of pharmacogenomic panel-testing in primary care in the Netherlands utilizing a theoretical framework. J Clin Med. 2020;9(3):814. doi:10.3390/jcm9030814
   PubMed Web of Science ®Google Scholar
• Frigon MP, Blackburn MÈ, Dubois-Bouchard C, Gagnon AL, Tardif S, Tremblay K. Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients. Pharmacogenomics. 2019;20(8):589–598. doi:10.2217/pgs-2019-0004
   PubMed Web of Science ®Google Scholar
• Haga SB. Challenges of development and implementation of point of care pharmacogenetic testing. Expert Rev Mol Diagn. 2016;16(9):949–960. doi:10.1080/14737159.2016.1211934
   PubMed Web of Science ®Google Scholar
• Abou Diwan E, Zeitoun RI, Abou Haidar L, Cascorbi I, Khoueiry Zgheib N. Implementation and obstacles of pharmacogenetics in clinical practice: an international survey. Br J Clin Pharmacol. 2019;85(9):2076–2088. doi:10.1111/bcp.13999
   PubMed Web of Science ®Google Scholar
• Stäuble CK, Lampert ML, Mikoteit T, Hatzinger M, Hersberger KE, Meyer Zu Schwabedissen HE. Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: a Case Report. Int J Mol Sci. 2021;22(12):6480. doi:10.3390/ijms22126480
   PubMed Web of Science ®Google Scholar
• Stäuble CK, Lampert ML, Mikoteit T, Hatzinger M, Hersberger KE, Meyer Zu Schwabedissen HE. Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B6*6 and CYP2C19*17 variants: a case report. Pharmacogenomics. 2020. doi:10.2217/pgs-2020-0087
   PubMed Web of Science ®Google Scholar
• Stäuble CK, Meier R, Lampert ML, et al. Case report: non-response to fluoxetine in a homozygous 5-HTTLPR S-allele carrier of the serotonin transporter gene. Front Psychiatry. 2022:13. doi:10.3389/fpsyt.2022.942268
   Web of Science ®Google Scholar
• Jeiziner C, Stäuble CK, Lampert ML, Hersberger KE, Meyer Zu Schwabedissen HE. Enriching medication review with a pharmacogenetic profile - a case of tamoxifen adverse drug reactions. Pharmgenomics Pers Med. 2021;14:279–286. doi:10.2147/PGPM.S285807
   PubMed Web of Science ®Google Scholar
• Jeiziner C, Allemann SS, Hersberger KE, Meyer Zu Schwabedissen HE. Is pharmacogenetic panel testing applicable to low-dose methotrexate in rheumatoid arthritis? - A case report. Pharmgenomics Pers Med. 2022;15:465–475. doi:10.2147/PGPM.S354011
   PubMed Web of Science ®Google Scholar
• Stäuble CK, Lampert ML, Mikoteit T, Hatzinger M, Hersberger KE, Meyer Zu Schwabedissen HE. Pharmacogenetic-guided antidepressant selection as an opportunity for interprofessional collaboration: a case report. Life. 2021;11(7):673. doi:10.3390/life11070673
   PubMedGoogle Scholar
• Stäuble CK, Jeiziner C, Bollinger A, et al. A guide to a pharmacist-led pharmacogenetic testing and counselling service in an interprofessional healthcare setting. Pharmacy. 2022;10(4):86. doi:10.3390/pharmacy10040086
   Web of Science ®Google Scholar
• mediQ. Interaktions-Check; 2023. Available from: https://www.mediq.ch/. Accessed June 5, 2023.
   Google Scholar
• McInnes G, Lavertu A, Sangkuhl K, Klein TE, Whirl-Carrillo M, Altman RB. Pharmacogenetics at Scale: an Analysis of the UK Biobank. Clin Pharmacol Ther. 2021;109(6):1528–1537. doi:10.1002/cpt.2122
   PubMed Web of Science ®Google Scholar
• Wittwer NL, Meier CR, Huber CA, Meyer Zu Schwabedissen HE, Allemann S, Schneider C. Utilization of drugs with pharmacogenetic dosing recommendations in Switzerland: a descriptive study using the helsana database. Pharmgenomics Pers Med. 2022;15:967–976. doi:10.2147/PGPM.S382214
   PubMed Web of Science ®Google Scholar
• Kimpton JE, Carey IM, Threapleton CJD, et al. Longitudinal exposure of English primary care patients to pharmacogenomic drugs: an analysis to inform design of pre-emptive pharmacogenomic testing. Br J Clin Pharmacol. 2019;85(12):2734–2746. doi:10.1111/bcp.14100
   PubMed Web of Science ®Google Scholar
• Kessler RC, Avenevoli S, Costello EJ, et al. Design and field procedures in the US National Comorbidity Survey Replication Adolescent Supplement (NCS-A). Int J Methods Psychiatr Res. 2009;18(2):69–83. doi:10.1002/mpr.279
   PubMed Web of Science ®Google Scholar
• Boyd A, Van de Velde S, Vilagut G, et al. Gender differences in mental disorders and suicidality in Europe: results from a large cross-sectional population-based study. J Affect Disord. 2015;173:245–254. doi:10.1016/j.jad.2014.11.002
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Bharat C, Glantz MD, et al. The epidemiology of drug use disorders cross-nationally: findings from the WHO’s World Mental Health Surveys. Int J Drug Policy. 2019;71:103–112. doi:10.1016/j.drugpo.2019.03.002
   PubMed Web of Science ®Google Scholar
• Bundesamt für Statistik. Psychische Gesundheit; 2017. Available from: https://www.bfs.admin.ch/bfs/de/home/statistiken/gesundheit/gesundheitszustand/psychische.html. Accessed June 5, 2023.
   Google Scholar
• Kvien TK, Uhlig T, Ødegård S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci. 2006;1069:212–222. doi:10.1196/annals.1351.019
   PubMed Web of Science ®Google Scholar
• Favalli EG, Biggioggero M, Crotti C, Becciolini A, Raimondo MG, Meroni PL. Sex and management of rheumatoid arthritis. Clin Rev Allergy Immunol. 2019;56(3):333–345. doi:10.1007/s12016-018-8672-5
   PubMed Web of Science ®Google Scholar
• Yu C, Liu C, Jiang J, et al. Gender differences in rheumatoid arthritis: interleukin-4 plays an important role. J Immunol Res. 2020;2020:4121524. doi:10.1155/2020/4121524
   PubMed Web of Science ®Google Scholar
• Watson S, Caster O, Rochon PA. Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century. eClinicalMedicine. 2019;17. doi:10.1016/j.eclinm.2019.10.001
   PubMedGoogle Scholar
• Tharpe N. Adverse drug reactions in women’s health care. J Midwifery Women’s Health. 2011;56(3):205–213. doi:10.1111/j.1542-2011.2010.00050.x
   PubMed Web of Science ®Google Scholar
• van Schaik RHN, Müller DJ, Serretti A, Ingelman-Sundberg M. Pharmacogenetics in Psychiatry: an Update on Clinical Usability. Front Pharmacol. 2020;11:575540. doi:10.3389/fphar.2020.575540
   PubMed Web of Science ®Google Scholar
• Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 1992;49(10):809–816. doi:10.1001/archpsyc.1992.01820100053010
   PubMed Web of Science ®Google Scholar
• Phan L, Jin Y, Zhang H, et al. National Center for Biotechnology Information, U.S. National Library of Medicine. ALFA: Allele Frequency Aggregator; 2020. Available from: https://www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/. Accessed June 5, 2023.
   Google Scholar
• Elliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. PLoS One. 2017;12(2):e0170905. doi:10.1371/journal.pone.0170905
   PubMed Web of Science ®Google Scholar
• Finkelstein J, Friedman C, Hripcsak G, Cabrera M. Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study. Pharmgenomics Pers Med. 2016;9:107–116. doi:10.2147/PGPM.S117014
   PubMed Web of Science ®Google Scholar
• Pérez V, Salavert A, Espadaler J, et al. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry. 2017;17(1):250. doi:10.1186/s12888-017-1412-1
   PubMedGoogle Scholar
• Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888–896. doi:10.1002/cpt.2149
   PubMed Web of Science ®Google Scholar
• Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM. Pharmacogenetics Guidelines: overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines. Front Pharmacol. 2021;11:595219. doi:10.3389/fphar.2020.595219
   PubMed Web of Science ®Google Scholar
• Asiimwe IG, Pirmohamed M. Drug-drug-gene interactions in cardiovascular medicine. Pharmgenomics Pers Med. 2022;15:879–911. doi:10.2147/PGPM.S338601
   PubMed Web of Science ®Google Scholar
• Wiss FM, Stäuble CK, Meyer Zu Schwabedissen HE, Allemann SS, Lampert ML. Pharmacogenetic Analysis Enables Optimization of Pain Therapy: a Case Report of Ineffective Oxycodone Therapy. J Personalized Med. 2023;13(5):829. doi:10.3390/jpm13050829
   PubMed Web of Science ®Google Scholar
• Swen JJ, van der Wouden CH, Manson LE, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401(10374):347–356. doi:10.1016/S0140-6736(22)01841-4
   PubMed Web of Science ®Google Scholar
• Stäuble CK, Lampert ML, Allemann S, et al. Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial. Trials. 2021;22(1):919. doi:10.1186/s13063-021-05724-5
   PubMed Web of Science ®Google Scholar